Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 2
Submit an article Journal homepage
180
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia

Buendía Jefferson Antonioa Department of Surgery, Research Group in Pharmacology and Toxicology ”INFARTO”. Department of Pharmacology and Toxicology, University of Antioquia, Medellín, ColombiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2404-6612View further author information
ORCID Icon,
Diana Guerrero Patiñob Hospital Infantil Concejo De Medellín, Medellin, ColombiaView further author information
&
Melisa Lopez Morenob Hospital Infantil Concejo De Medellín, Medellin, ColombiaView further author information
Pages 299-305 | Received 25 Apr 2021, Accepted 16 Jun 2021, Published online: 28 Jun 2021

References

  • To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):204.
  • Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–323.
  • Sánchez J, Morales E, Santamaria L-C, et al. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021;14(3):100520.
  • Global Iniciative for Asthma Management and Prevention 2020 [cited 2021 Jun 23]. Available from: www.ginaasthma.org.
  • FitzGerald JM, Bleecker ER, Nair P, et al., Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 388(10056): 2128–2141. 2016.
  • Pelaia C, Busceti MT, Crimi C, et al. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020;129:110444.
  • Pelaia C, Busceti MT, Vatrella A, et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther. 2019;58:101830.
  • Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192.
  • Excellence. NIfHaC. Benralizumab for treating severe eosinophilic asthma. 2018.
  • Andersson M, Janson C, Kristensen T, et al. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden. J Med Econ. 2020;23(8):877–884.
  • Florez-Tanus A, Parra D, Zakzuk J, et al. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018;11(1):26.
  • Einarson TR, Bereza BG, Nielsen TA, et al. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550–563.
  • Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting practices task force. Value Health. 2013;16(2):231–250.
  • Departamento, Nacional, (DANE) DE. Archivo Nacional de Datos 2019. [cited 2021 Jun 23]. Available from: https://sitios.dane.gov.co/anda-index.
  • (DANE) DNdE. Archivo nacional de datos 2019 [cited 2021 Jun 23]. Available from: https://sitios.dane.gov.co/anda-index.
  • Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 1998;18(1):95–109.
  • Dennis RJ, Caraballo L, Garcia E, et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17.
  • Salud. IdETe. Manual metodológico para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. 2014.
  • Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51(6):836–844.
  • Padilla-Galo A, Levy-Abitbol R, Olveira C, Padilla-Galo A, Levy-Abitbol R, Olveira C, Valencia Azcona B, Perez Morales M, Rivas-Ruiz F, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184.
  • Asthma G Global strategy for asthma management and prevention 2021 [ cited 2021 May 06]. https://ginasthma.org.
  • Llanos JP, Ortega H, Bogart M, et al. Real-world effectiveness of Mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;13:77–87.
  • Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798.
  • Estadisticas DAN. Índice de Precios al Consumidor - IPC 2020. [cited 2021 Jun 23]. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.